| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/22/2001 | CA2381979A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | CA2381976A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | CA2381975A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | CA2381780A1 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | CA2381700A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2380979A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | CA2380966A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | CA2380940A1 Substances and agents for positively influencing collagen |
| 02/22/2001 | CA2380786A1 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | CA2377646A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | CA2377637A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/21/2001 | EP1076663A1 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
| 02/21/2001 | EP1076651A1 Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
| 02/21/2001 | EP1076650A1 Aryl fused azapolycyclic compounds |
| 02/21/2001 | EP1076644A1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/21/2001 | EP1076643A1 Biphenyl derivatives |
| 02/21/2001 | EP1076641A1 Inhibitors of impdh enzyme |
| 02/21/2001 | EP1076558A1 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens |
| 02/21/2001 | EP1076556A1 Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| 02/21/2001 | EP0784683B1 Tie-2 ligands, methods of making and uses thereof |
| 02/21/2001 | EP0526452B1 Hybrid immunoglobulins |
| 02/21/2001 | CN1284956A Novel bispidine antiarrhythmic compounds |
| 02/21/2001 | CN1284948A Indezole bioisostere replacement of catechol in therafeutically active compounds |
| 02/21/2001 | CN1284947A Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/21/2001 | CN1284946A Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/21/2001 | CN1284944A Integrin receptor antagonists |
| 02/21/2001 | CN1284942A Matrix metalloprotease inhibitors |
| 02/21/2001 | CN1284941A Novel antiarrhythmic compounds |
| 02/21/2001 | CN1284880A Hyperhydrated citicoline, process and use |
| 02/21/2001 | CN1284865A Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/21/2001 | CN1284862A Topical compositions for prostaglandin E1 delivery |
| 02/21/2001 | CN1284367A Hemiplegia treating Chinese medicine |
| 02/21/2001 | CN1284355A Medicine for treating cardiac and cerebral vascular diseases and its preparation |
| 02/21/2001 | CN1284351A Red sage containing medicine composition and its preparation and use |
| 02/21/2001 | CN1284347A Chinese medicine for preventing and curing cardiac and cerebral vascular diseases |
| 02/21/2001 | CN1284338A Asclerol extracting process from waste liquid after producing Heparin sodium |
| 02/21/2001 | CN1284337A Piles medicine |
| 02/21/2001 | CN1284331A Application of 5,3',5'-trihydroxy-methoxyl dihydroflavone in preparing medicine |
| 02/21/2001 | CN1062269C Novel (R)-5-carbamyl-8-fluoro-3-N, N-disubstituted amino-3, 4-dihydro-2H-1-benzopyranes |
| 02/21/2001 | CN1062161C Process for preparation of stable fleabane extract injection |
| 02/21/2001 | CN1062160C Drug for curing cerebral infarction |
| 02/21/2001 | CN1062145C Piles curing liquid |
| 02/21/2001 | CN1062143C Medicinal health liquid and beer, beverage, beet and instant noodle containing the same |
| 02/21/2001 | CN1062133C Medicine for treating hypertension |
| 02/20/2001 | US6191304 Vitronectin receptor antagonists |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191160 Spiro-indolines as Y5 receptor antagonists |
| 02/20/2001 | US6191158 Respiratory system disorders; cardiovascular disorders; anticholesterol agents |
| 02/20/2001 | US6191157 Anticholesterol agents; cardiovascular disorders |
| 02/20/2001 | US6191152 Cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6191149 Heterocyclic derivative and medicine |
| 02/20/2001 | US6191147 Pyrazole compounds and uses thereof |
| 02/20/2001 | US6191140 Potassium channel modulators; muscle relaxants; controlling cell membranes |
| 02/20/2001 | US6191130 Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors |
| 02/20/2001 | US6191127 Antiinflammatory agents, autoimmune diseases, cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6190875 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 02/20/2001 | US6190694 Rendering chitosan into powder; adding chitosan powder, powder comprising organic acid and salt thereof, and an emulsifier to an oil or fat; stirring mixture so as to suspend powders, obtain a gel-like stock and gelatin solution for encapsulation |
| 02/20/2001 | US6190693 Administering pharmaceutical formulation comprising hormonal replacememt for treating or preventing menopausal condition and folic acid |
| 02/20/2001 | CA2192289C Substituted heterocyclic derivatives |
| 02/20/2001 | CA2191789C Biaromatic compounds containing an adamantyl group in ortho position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 02/20/2001 | CA2158991C Adipocyte differentiation inhibiting peptide and adipocyte differentiation inhibiting agent using the peptide as active component thereof |
| 02/20/2001 | CA2125037C Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality |
| 02/20/2001 | CA2076749C Vasoactive vasotocin derivatives |
| 02/20/2001 | CA2054419C Process for producing 6-(3-dimethylaminopropionyl)forskolin |
| 02/15/2001 | WO2001011086A2 Methods of screening for angiogenesis modulators |
| 02/15/2001 | WO2001011064A2 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy |
| 02/15/2001 | WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | WO2001011038A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001010905A1 Medicinal compositions for inhibiting abnormal proliferation of vascular smooth muscle cells |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010859A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | WO2001010851A1 Process for the preparation of lysine-carboxyanhydride intermediates in the synthesis of lisinopril |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010844A1 φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM |
| 02/15/2001 | WO2001010841A2 Fluorene derivatives as integrin inhibitors |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010831A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 02/15/2001 | WO2001010829A1 Novel vitamin d analogues |
| 02/15/2001 | WO2001010819A1 Nitroxy derivatives of (r) and (s)-carnitine |
| 02/15/2001 | WO2001010816A2 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 02/15/2001 | WO2001010458A1 Use of neurotoxin for treating cardiac muscle disorders |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010433A1 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 02/15/2001 | WO2001010430A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 02/15/2001 | WO2001010425A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 02/15/2001 | WO2001010423A2 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010378A2 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/15/2001 | WO2001010344A1 Nitric oxide releasing medical devices |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity |
| 02/15/2001 | WO2000066584B1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |